PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025
AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent productivity platform ...
2026-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
SHANGHAI , April 30, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical ...
2026-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D , 600 mg QD). Phase 2 clinical outcomes include: ...
2026-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
TOKYO and NEWARK, Del. , April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research ...
2026-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
HONG KONG , April 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's ...
2026-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidates
TOKYO and NEWARK, Del. , April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, announces its collaboration ...
2026-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
TLX597-Tx is a PSMA [1] -targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. OPTIMAL-PSMA [2] initial dosimetry ...
2026-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Infinitus Presents Human Evidence-Based Research Findings at FFC 2026
GUANGZHOU, China , April 30, 2026 /PRNewswire/ -- Ma Jun, Vice President and Chief Science Innovation Officer of Infinitus (China) Company Ltd., was invited to attend the Functional Food Conference 2026 ...
2026-04-30T    Biotechnology   Food/Beverages   Health Care/Hospital 
Navinci launches Omni kit - the next generation of spatial interactomics
UPPSALA, Sweden , April 29, 2026 /PRNewswire/ --  Navinci today announces the launch of Omni , breakthrough fully customized kits designed to transform how scientists study protein function ...
2026-04-29T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million
Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors ...
2026-04-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.